# U S Physical Therapy Inc: Form 10-Q for the period ended Sep 30, 2015

- Company: [U S Physical Therapy Inc](/companies/usph.md) (CIK 885978)
- Form: 10-Q
- Filed: 2015-11-05
- Accepted by EDGAR: Nov 5, 2015, 10:18 ET
- Period: 2015-09-30
- Accession: 0001140361-15-039748
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/885978/000114036115039748/form10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/885978/000114036115039748/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2015-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2015-07-01 to 2015-09-30 | $84.0m | us-gaap:SalesRevenueNet |
| Revenue | 9 months, 2015-01-01 to 2015-09-30 | $244.6m | us-gaap:SalesRevenueNet |
| Gross profit | 3 months, 2015-07-01 to 2015-09-30 | $18.9m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2015-01-01 to 2015-09-30 | $56.9m | us-gaap:GrossProfit |
| Operating income | 3 months, 2015-07-01 to 2015-09-30 | $11.9m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2015-01-01 to 2015-09-30 | $34.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2015-07-01 to 2015-09-30 | $255.0k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2015-01-01 to 2015-09-30 | $765.0k | us-gaap:InterestExpense |
| Income tax | 3 months, 2015-07-01 to 2015-09-30 | $3.7m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2015-01-01 to 2015-09-30 | $10.6m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2015-07-01 to 2015-09-30 | $5.8m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2015-01-01 to 2015-09-30 | $16.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2015-07-01 to 2015-09-30 | $0.47 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2015-01-01 to 2015-09-30 | $1.29 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2015-07-01 to 2015-09-30 | $0.47 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2015-01-01 to 2015-09-30 | $1.29 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2015-07-01 to 2015-09-30 | 12,421,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2015-01-01 to 2015-09-30 | 12,382,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2015-01-01 to 2015-09-30 | $28.9m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 9 months, 2015-01-01 to 2015-09-30 | $4.7m | us-gaap:PaymentsToAcquireProductiveAssets |
| Dividends paid | 9 months, 2015-01-01 to 2015-09-30 | $5.6m | us-gaap:PaymentsOfDividendsCommonStock |
| Cash and equivalents | at 2015-09-30 | $20.6m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2015-09-30 | $63.7m | us-gaap:AssetsCurrent |
| Total assets | at 2015-09-30 | $276.1m | us-gaap:Assets |
| Current liabilities | at 2015-09-30 | $21.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2015-09-30 | $81.0m | us-gaap:Liabilities |
| Long-term debt | at 2015-09-30 | $47.7m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2015-09-30 | $1.4m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2015-09-30 | $158.9m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 31,585 characters.

The following is a discussion of our historical consolidated financial condition and results of operations, and should be read in conjunction with (i) our historical consolidated financial statements and accompanying notes thereto included elsewhere in this Quarterly Report on Form 10-Q; (ii) our Annual Report on Form 10-K for the year ended December 31, 2014 filed with the Securities and Exchange Commission (the “SEC”) on March 12, 2015; and (iii) our management’s discussion and analysis of financial condition and results of operations included in our 2014 Form 10-K. This discussion includes forward-looking statements that are subject to risk and uncertainties. This discussion includes forward-looking statements that are subject to risk and uncertainties. Actual results may differ substantially from the statements we make in this section due to a number of factors that are discussed in “Forward-Looking Statements” herein and “Part I – Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2014

References to “we,” “us,” “our” and the “Company” shall mean U.S. Physical Therapy, Inc. and its subsidiaries.

### EXECUTIVE SUMMARY

### Our Business

We operate outpatient physical therapy clinics that provide preventive and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. As of September 30, 2015, we operated 506 clinics in 42 states.

We also manage physical therapy facilities for third parties, primarily physicians, with 20 third-party facilities under management as of September 30, 2015.

During the nine months of 2015 and the year ended 2014, we acquired the following clinic groups:

| Acquisition | Date 2015 | % Interest Acquired | Number of Clinics |
| --- | --- | ---: | ---: |
| Jan 2015 Acquisition | Jan 31 | 60% | 9 |
| April 2015 Acquisition | April 30 | 70% | 3 |
| June 2015 Acquisition | June 30 | 70% | 4 |
|  | **2014** |  |  |
| April 2014 Acquisition | April 30 | 70% | 13 |
| August 2014 Acquisition | August 1 | 100% | 3 |

On August 31, 2015, we acquired a 60% interest in a single physical therapy clinic. The purchase price was $150,000 in cash. On June 30, 2015, we acquired a 70% interest in a four-clinic physical therapy practice. The purchase price was $3.6 million in cash and $0.7 million in seller notes that are payable plus accrued interest, in June 2018. On April 30, 2015, we acquired a 70% interest in a three-clinic physical therapy practice. The purchase price was $4.7 million in cash and $150,000 in a seller note that is payable in two principal installments of $75,000 each, plus accrued interest, in April 2016 and 2017. On January 31, 2015, we acquired a 60% interest in a nine-clinic physical therapy practice. The purchase price for the 60% interest was $6.7 million in cash and $0.5 million in a seller note that is payable in two principal installments of $250,000 each, plus accrued interest, in January 2016 and 2017.

On April 30, 2014, we acquired a 70% interest in a 13-clinic physical therapy practice. The purchase price for the 70% interest was $10.6 million in cash and $0.4 million in a seller note that is payable in two principal installments totaling $200,000 each, plus accrued interest, in April 2015 and 2016. On August 1, 2014, we acquired a 100% interest in a 3-clinic physical therapy practice. The purchase price for the 100% interest was $1.0 million in cash. In addition, during 2014, the Company acquired three individual clinic practices for an aggregate of $595,000 in cash.

The results of operations of the acquired clinics have been included in our consolidated financial statements since the date of their acquisition.

### Selected Operating and Financial Data

The following table presents selected operating and financial data that we believe are key indicators of our operating performance.

|  | For the Three Months Ended September 30, 2015 | 2014 | For the Nine Months Ended September 30, 2015 | 2014 |
| --- | ---: | ---: | ---: | ---: |
| Number of clinics, at the end of period | 506 | 489 | 506 | 489 |
| Working days | 64 | 64 | 191 | 191 |
| Average visits per day per clinic | 24.3 | 23.0 | 23.9 | 22.6 |
| Total patient visits | 782,140 | 719,271 | 2,271,862 | 2,081,907 |
| Net patient revenue per visit | $105.04 | $105.92 | $105.38 | $106.18 |

### RESULTS OF OPERATIONS

### Three Months Ended September 30, 2015 Compared to the Three Months Ended September 30, 2014

Net revenues increased to $84.0 million for the three months ended September 30, 2015 (“2015 Third Quarter”) from $77.7 million for the three months ended September 30, 2014 (“2014 Third Quarter”) primarily due to an increase in visits of 62,800 from 719,300 for the 2014 Third Quarter to 782,100 for the 2015 Third Quarter offset by a decrease in the average net patient revenue per visit for the 2015 Third Quarter to $105.04 from $105.92 in the 2014 Third Quarter.

Net income attributable to our common shareholders prior to revaluation of redeemable non-controlling interests, net of tax, (“operating results”), for the 2015 Third Quarter was $5.8 million versus $5.2 million for the 2014 Third Quarter. Diluted earnings per share from operating results were $0.47 for the 2015 period and $0.43 for the comparable 2014 period. Total diluted shares were 12.4 million for the 2015 Third Quarter and 12.2 million for the 2014 Third Quarter.

### Net Patient Revenues

Net patient revenues increased to $82.2 million for the 2015 Third Quarter from $76.2 million for the 2014 Third Quarter, an increase of $6.0 million, or 7.8%, due to visits of 52,700 from clinics opened and acquired between October 1, 2014 and September 30, 2015 (“New Clinics”) and an increase in visits of 10,100 from clinics opened or acquired prior to October 1, 2014 (“Mature Clinics”) offset by a decrease in the net patient revenue per visit of $0.88.

Net patient revenues related to New Clinics amounted to $5.4 million for the 2015 Third Quarter and net patient revenues for Mature Clinics increased by $0.6 million for the 2015 Third Quarter as compared to the 2014 Third Quarter.

Net patient revenues are based on established billing rates less allowances and discounts for patients covered by contractual programs and workers’ compensation. Net patient revenues are determined after contractual and other adjustments relating to patient discounts from certain payors. Payments received under these programs are based on predetermined rates and are generally less than the established billing rates.

### Other Revenues

Other revenues increased $0.4 million in the 2015 Third Quarter to $1.9 million from $1.5 million in the 2014 Third Quarter due to the increased number of management contracts.

### Clinic Operating Costs

Clinic operating costs were $65.2 million, or 77.5% of net revenues, for the 2015 Third Quarter and $59.0 million, or 75.9% of net revenues, for the 2014 Third Quarter. The increase was primarily attributable to $5.1 million in operating costs of New Clinics and by an increase in operating costs of $1.1 million for Mature Clinics. Each component of clinic operating costs is discussed below:

C**linic Operating Costs—Salaries and Related Costs**

Salaries and related costs increased to $46.6 million for the 2015 Third Quarter from $41.8 million for the 2014 Third Quarter, an increase of $4.8 million. Salaries and related costs for New Clinics amounted to $3.5 million for the 2015 Third Quarter. Salaries and related costs for Mature Clinics increased by $1.3 million for the 2015 Third Quarter as compared to the 2014 Third Quarter. Included in salaries and related costs in the 2015 quarter is $230,000 of compensation and severance costs for employee terminations as part of our previously announced cost-cutting plan. Salaries and related costs as a percentage of net revenues were 55.4% for the 2015 Third Quarter and 53.8% for the 2014 Third Quarter.

### Clinic Operating Costs—Rent, Clinic Supplies, Contract Labor and Other

Rent, clinic supplies, contract labor and other were $17.4 million for the 2015 Third Quarter and $16.1 million for the 2014 Third Quarter. For New Clinics, rent, clinic supplies, contract labor and other amounted to $1.5 million for the 2015 Third Quarter. For Mature Clinics, rent, clinic supplies, contract labor and other decreased by $0.2 million in the 2015 Third Quarter compared to the 2014 Third Quarter. Rent, clinic supplies, contract labor and other as a percentage of net revenues was 20.7% for the 2015 Third Quarter and for the 2014 Third Quarter.

### Clinic Operating Costs—Provision for Doubtful Accounts

The provision for doubtful accounts was $1.1 million for the 2015 Third Quarter and for the 2014 Third Quarter. The provision for doubtful accounts for patient accounts receivable as a percentage of net patient revenues was 1.3% for 2015 Third Quarter period and 1.4% the 2014 Third Quarter.

Our provision for doubtful accounts for patient accounts receivable as a percentage of total patient accounts receivable was 4.2% at September 30, 2015, as compared to 4.8% at December 31, 2014. Our day’s sales outstanding were 37 days at September 30, 2015 and 39 days at December 31, 2014.

### Corporate Office Costs

Corporate office costs, consisting primarily of salaries and benefits of corporate office personnel, rent, insurance costs, depreciation and amortization, travel, legal, accounting, professional, and recruiting fees, were $6.9 million for the 2015 Third Quarter and $7.5 million for the 2014 Third Quarter. The decrease of $0.6 million is primarily attributable to a reduction in accrued incentive compensation. As a percentage of net revenues, corporate office costs were 8.2% for the 2015 Third Quarter and 9.6% for the 2014 Third Quarter.

### Interest Expense

Interest expense decreased to $0.3 million in the 2015 Third Quarter compared to $0.2 million in the 2014 Third Quarter. At September 30, 2015, $46.0 million was outstanding under our revolving credit agreement.

### Provision for Income Taxes

The provision for income taxes was $3.7 million for the 2015 Third Quarter and $3.6 million for the 2014 Third Quarter. During the 2015 and 2014 Third Quarters, we accrued state and federal income taxes at an effective tax rate (provision for taxes divided by the difference between income before taxes and net income attributable to non-controlling interests) of 38.6% and 41.0%, respectively. The 2015 third quarter includes an adjustment of the 2015 expected annual tax rate to 39.5% from 40.0% based on an analysis of the 2015 results inclusive of non-deductible tax items.

### Non-controlling Interests

Net income attributable to non-controlling interests was $2.2 million for the 2015 Third Quarter and for the 2014 Third Quarter. As a percentage of operating income before corporate office costs, net income attributable to non-controlling interests was 11.9% for the 2015 Third Quarter and 11.7% for the 2014 Third Quarter.

### Nine Months Ended September 30, 2015 Compared to the Nine Months Ended September 30, 2014

Net revenues increased to $244.6 million for the nine months ended September 30, 2015 (“2015 First Nine Months”) from $225.7 million for the nine months ended September 30, 2014 (“2014 First Nine Months”) primarily due to an increase in visits of 190,000 from 2,081,900 for the 2014 First Nine Months to 2,271,900 for the 2015 First Nine Months offset by a decrease of $0.80 in the net patient revenue per visit.

Operating results for the 2015 First Nine Months was $16.3 million versus $15.9 million for the 2014 First Nine Months. Diluted earnings per share from operating results were $1.32 for the 2015 period and $1.30 in the 2014 period. Total diluted shares were 12.4 million for the 2015 First Nine Months and 12.2 million for the 2014 First Nine Months.

### Net Patient Revenues

Net patient revenues increased to $239.4 million for the 2015 First Nine Months from $221.1 million for the 2014 First Nine Months, an increase of $18.3 million due to an increase in visits of 102,400 from New Clinics and an increase in visits of 87,600 from Mature Clinics offset by a decrease in the average net revenue per visit for the current period of $0.80 from $106.18 for the 2014 period to $105.38 for the 2015 period.

Net patient revenues related to New Clinics amounted to $10.3 million for the 2015 First Nine Months and net patient revenues for Mature Clinics increased by $8.1 million for the 2015 First Nine Months as compared to the 2014 First Nine Months primarily due to the April 2014 Acquisition having a full nine months of revenue in 2015 and only five months in 2014.

Net patient revenues are based on established billing rates less allowances and discounts for patients covered by contractual programs and workers’ compensation. Net patient revenues are determined after contractual and other adjustments relating to patient discounts from certain payors. Payments received under these programs are based on predetermined rates and are generally less than the established billing rates.

### Other Revenues

Other revenues increased $0.5 million in the 2015 First Nine Months to $5.2 million from $4.6 million in the 2014 First Nine Months due to the increased number of management contracts.

### Clinic Operating Costs

Clinic operating costs were $187.7 million, or 76.8% of net revenues, for the 2015 First Nine Months and $168.5 million, or 74.6% of net revenues, for the 2014 First Nine Months. The increase was primarily attributable to $9.6 million in operating costs of New Clinics and an increase in operating costs of $9.6 million for Mature Clinics primarily due to clinics opened or acquired in the first nine month of 2014 having a full nine months of expenses in 2015. Each component of clinic operating costs is discussed below:

### Clinic Operating Costs—Salaries and Related Costs

Salaries and related costs increased to $134.0 million for the 2015 First Nine Months from $119.9 million for the 2014 First Nine Months, an increase of $14.1 million. Salaries and related costs for New Clinics amounted to $6.7 million for the 2015 First Nine Months. Salaries and related costs for Mature Clinics increased by $7.4 million for the 2015 First Nine Months as compared to the 2014 First Nine Months. Included in salaries and related costs in the 2015 period is $230,000 of compensation and severance costs for employee terminations as part of our previously announced cost-cutting plan. Salaries and related costs as a percentage of net revenues were 54.8% for the 2015 First Nine Months and 53.1% for the 2014 First Nine Months.

### Clinic Operating Costs—Rent, Clinic Supplies, Contract Labor and Other

Rent, clinic supplies, contract labor and other were $50.4 million for the 2015 First Nine Months and $45.5 million for the 2014 First Nine Months. For New Clinics, rent, clinic supplies, contract labor and other amounted to $2.8 million for the 2015 First Nine Months. For Mature Clinics, rent, clinic supplies, contract labor and other increased by $2.1 million in the 2015 First Nine Months compared to the 2014 First Nine Months. Rent, clinic supplies, contract labor and other as a percentage of net revenues was 20.6% for the 2015 First Nine Months and 20.2% for the 2014 First Nine Months.

### Clinic Operating Costs—Provision for Doubtful Accounts

The provision for doubtful accounts was $3.1 million for both the 2015 First Nine Months and the 2014 First Nine Months. The provision for doubtful accounts for patient accounts receivable as a percentage of net patient revenues was 1.3% for the 2015 First Nine Months and 1.4% for the 2014 First Nine Months.

Our provision for doubtful accounts for patient accounts receivable as a percentage of total patient accounts receivable was 4.2% at September 30, 2015, as compared to 4.8% at December 31, 2014. Our days sales outstanding was 37 days at September 30, 2015 and 39 days at December 31, 2014.

### Corporate Office Costs

Corporate office costs, consisting primarily of salaries and benefits of corporate office personnel, rent, insurance costs, depreciation and amortization, travel, legal, accounting, professional, and recruiting fees, were $22.2 million for both the 2015 First Nine Months and the 2014 First Nine Months. As a percentage of net revenues, corporate office costs were 9.1% for the 2015 First Nine Months and 9.8% for 2014 First Nine Months.

### Interest Expense

Interest expense was the same $0.8 million in both the 2015 First Nine Months and in the 2014 First Nine Months. At September 30, 2015, $46.0 million was outstanding under our revolving credit agreement.

### Provision for Income Taxes

The provision for income taxes was $10.6 million for the 2015 First Nine Months and $11.0 million for the 2014 First Nine Months. During the 2015 and 2014 First Nine Months, we accrued state and federal income taxes at an effective tax rate (provision for taxes divided by the difference between income before taxes and net income attributable to non-controlling interests) of 39.5% and 41%, respectively.

### Non-controlling Interests

Net income attributable to non-controlling interests was $7.0 million for the 2015 First Nine Months and $7.3 million for the 2014 First Nine Months or as a percentage of operating income before corporate office costs was 12.4% for the 2015 First Nine Months and 12.7% for the 2014 First Nine Months.

### LIQUIDITY AND CAPITAL RESOURCES

We believe that our business is generating sufficient cash flow from operations to allow us to meet our short-term and long-term cash requirements, other than those with respect to future acquisitions. At September 30, 2015 and December 31, 2014, we had $20.6 million and $14.3 million, respectively, in cash. Although the start-up costs associated with opening new clinics and our planned capital expenditures are significant, we believe that our cash and unused availability under our revolving credit agreement are sufficient to fund the working capital needs of our operating subsidiaries, future clinic development and acquisitions and investments through at least September 2016. The amount outstanding under our revolving credit facility was $46.0 million at September 30, 2015 compared to $34.5 million at December 31, 2014. At September 30, 2015 we had $79.0 million available under our revolving credit facility. Significant acquisitions would likely require financing under our revolving credit facility.

During the nine months ended September 30, 2015, $28.9 million was provided by operations and $11.5 million was drawn on our revolving credit agreement. The major uses of cash included: purchases of businesses ($14.4 million), distributions to non-controlling interest partners ($6.8 million), payments of cash dividends to our shareholders ($5.6 million), purchases of fixed assets ($4.7 million), purchases of non-controlling interests ($2.8 million) and payments on our notes payable ($0.6 million).

Effective December 5, 2013, we entered into an Amended and Restated Credit Agreement with a commitment for a $125.0 million revolving credit facility with a maturity date of November 30, 2018 (“Credit Agreement”). The Credit Agreement is unsecured and has loan covenants, including requirements that we comply with a consolidated fixed charge coverage ratio and consolidated leverage ratio. Proceeds from the Credit Agreement may be used for working capital, acquisitions, purchases of our common stock, dividend payments to our common shareholders, capital expenditures and other corporate purposes. The pricing grid is based on our consolidated leverage ratio with the applicable spread over LIBOR ranging from 1.5% to 2.2% or the applicable spread over the Base Rate ranging from 0.1% to 1%. Fees under the Credit Agreement include an unused commitment fee ranging from 0.1% to 0.25% depending on our consolidated leverage ratio and the amount of funds outstanding under the Credit Agreement. On September 30, 2015, we were in compliance with all of the covenants thereunder.

On August 31, 2015, we acquired a 60% interest in a single physical therapy clinic. The purchase price was $150,000 in cash. On June 30, 2015, we acquired a 70% interest in a four-clinic physical therapy practice. The purchase price was $3.6 million in cash and $0.7 million in seller notes that are payable plus accrued interest, in June 2018. On April 30, 2015, we acquired a 70% interest in a three-clinic physical therapy practice. The purchase price was $4.7 million in cash and $150,000 in a seller note that is payable in two principal installments of $75,000 each, plus accrued interest, in April 2016 and 2017. On January 31, 2015, we acquired a 60% interest in a nine-clinic physical therapy practice. The purchase price for the 60% interest was $6.7 million in cash and $0.5 million in a seller note that is payable in two principal installments of $250,000 each, plus accrued interest, in January 2016 and 2017.

Historically, we have generated sufficient cash from operations to fund our development activities and to cover operational needs. We plan to continue developing new clinics and making additional acquisitions. We also from time to time purchase the non-controlling interests in our Clinic Partnerships. Generally, any acquisition or purchase of non-controlling interests is expected to be accomplished using a combination of cash and financing. Significant acquisitions would likely require financing under our revolving credit facility.

We make reasonable and appropriate efforts to collect accounts receivable, including applicable deductible and co-payment amounts, in a consistent manner for all payor types. Claims are submitted to payors daily, weekly or monthly in accordance with our policy or payor’s requirements. When possible, we submit our claims electronically. The collection process is time consuming and typically involves the submission of claims to multiple payors whose payment of claims may be dependent upon the payment of another payor. Claims under litigation and vehicular incidents can take a year or longer to collect. Medicare and other payor claims relating to new clinics awaiting Medicare Rehab Agency status approval initially may not be submitted for six months or more. When all reasonable internal collection efforts have been exhausted, accounts are written off prior to sending them to outside collection firms. With managed care, commercial health plans and self-pay payor type receivables, the write-off generally occurs after the account receivable has been outstanding for at least 120 days.

We generally enter into various notes payable as a means of financing our acquisitions and purchases of non-controlling interests. Our present outstanding notes payable relate to certain of the acquisitions of businesses and a purchase of non-controlling interest that occurred in 2013 through 2015. For those acquisitions, we entered into several notes payables aggregating $3.1 million. Generally, the notes are payable in equal annual installments of principal over two years plus any accrued and unpaid interest. Interest accrues at various interest rates ranging from 3.25% to 4.0% per annum, subject to adjustment. In addition, we assumed leases with remaining terms of 1 month to 6 years for the operating facilities. At September 30, 2015, the balance on these notes payable was $3.1 million.

In conjunction with the above mentioned acquisitions, in the event that a limited minority partner’s employment ceases at any time after three years from the acquisition date, we have agreed to repurchase that individual’s non-controlling interest at a predetermined multiple of earnings before interest and taxes.

As of September 30, 2015, we have accrued $2.0 million related to credit balances and overpayments due to patients and payors. This amount is expected to be paid in the next 12 months. Of this $2.0 million, $710,000 relates to a limited partnership in which we own a majority interest, which is in the process of resolving an investigation by the U.S. Department of Justice into certain Medicare billings that occurred between 2007 and 2009 at a single outpatient physical therapy clinic. It is expected that a settlement agreement will be entered into which will conclude the government’s review into whether certain physical therapy services provided to a limited number of Medicare patients at the clinic satisfied all of the criteria for payment by the Medicare program. The issue at the clinic related to a Medicare regulation, unique to a private practice setting, that requires a different level of supervision for a claim to qualify for payment when the services are performed by a licensed physical therapist assistant. The Medicare supervision requirements go beyond what is required under the state licensing law, the physical therapist assistant scope of practice, and professional standards of care. The limited partnership has tentatively agreed to pay $710,000 to resolve the matter. The settlement expense was estimated and accrued for in 2012. We, along with the limited partnership, have cooperated fully in the government review and the Company conducted its own internal audit of all of the Medicare claims submitted by that clinic during the relevant period in order to assist the government in determining the appropriate dollar amount that should be refunded. As is customary at the conclusion of such government investigations, it is anticipated that the limited partnership and the Company will enter into a Corporate Integrity Agreement (CIA) that will be incorporated into the Company’s existing comprehensive compliance program.

From September 2001 through December 31, 2008, our Board of Directors (“Board”) authorized us to purchase, in the open market or in privately negotiated transactions, up to 2,250,000 shares of our common stock. In March 2009, the Board authorized the repurchase of up to 10% or approximately 1,200,000 shares of our common stock (“March 2009 Authorization”). In connection with the March 2009 Authorization, we amended our bank credit agreement to permit share repurchases of up to $15,000,000. We are required to retire shares purchased under the March 2009 Authorization. Effective October 24, 2012, we amended the Credit Agreement to permit us to purchase, commencing on October 24, 2012 and at all times thereafter, up to $15,000,000 of our common stock subject to compliance with covenants.

There is no expiration date for the share repurchase program. As of September 30, 2015, there are currently an additional estimated 334,000 shares (based on the closing price of $44.89 on September 30, 2015) that may be purchased from time to time in the open market or private transactions depending on price, availability and our cash position. We did not purchase any shares of our common stock during the nine months ended September 30, 2015.

### FACTORS AFFECTING FUTURE RESULTS

The risks related to our business and operations include:

- changes as the result of government enacted national healthcare reform;
- changes in Medicare guidelines and reimbursement or failure of our clinics to maintain their Medicare certification status;
- business and regulatory conditions including federal and state regulations;
- governmental and other third party payor investigations and audits;
- compliance with federal and state laws and regulations relating to the privacy of individually identifiable patient information, and associated fines and penalties for failure to comply;
- changes in reimbursement rates or payment methods from third party payors including government agencies and deductibles and co-pays owed by patients;
- transition to ICD - 10 coding system;
- revenue and earnings expectations;
- general economic conditions;
- availability and cost of qualified physical therapists;
- personnel productivity;
- competitive, economic or reimbursement conditions in our markets which may require us to reorganize or close certain clinics and thereby incur losses and/or closure costs including the possible write-down or write-off of goodwill and other intangible assets;
- acquisitions, purchase of non-controlling interests (minority interests) and the successful integration of the operations of the acquired businesses;
- maintaining adequate internal controls;
- availability, terms, and use of capital; and
- weather and other seasonal factors.

See Risk Factors in Item 1A of our Annual Report on Form 10-K.

### Forward-Looking Statements

We make statements in this report that are considered to be forward-looking within the meaning under Section 21E of the Securities Exchange Act of 1934, as (the “Exchange Act”). These statements contain forward-looking information relating to our financial condition, results of operations, plans, objectives, future performance and business. These statements (often using words such as “believes”, “expects”, “intends”, “plans”, “appear”, “should” and similar words) involve risks and uncertainties that could cause actual results to differ materially from those we project. Included among such statements are those relating to opening new clinics, availability of personnel and the reimbursement environment. The forward-looking statements are based on our current views and assumptions and actual results could differ materially from those anticipated in such forward-looking statements as a result of certain risks, uncertainties, and factors, which include, but are not limited to:

- changes as the result of government enacted national healthcare reform;
- changes in Medicare guidelines and reimbursement or failure of our clinics to maintain their Medicare certification status;
- business and regulatory conditions including federal and state regulations;
- governmental and other third party payor investigations and audits;
- compliance with federal and state laws and regulations relating to the privacy of individually identifiable patient information, and associated fines and penalties for failure to comply;
- changes in reimbursement rates or payment methods from third party payors including government agencies and deductibles and co-pays owed by patients;
- transition to ICD - 10 coding system;
- revenue and earnings expectations;
- general economic conditions;
- availability and cost of qualified physical and occupational therapists;
- personnel productivity;
- competitive, economic or reimbursement conditions in our markets which may require us to reorganize or close certain clinics and thereby incur losses and/or closure costs including the possible write-down or write-off of goodwill and other intangible assets;
- acquisitions, purchase of non-controlling interests (minority interests) and the successful integration of the operations of the acquired businesses;
- maintaining adequate internal controls;
- availability, terms, and use of capital; and
- weather and other seasonal factors.

Many factors are beyond our control. Given these uncertainties, you should not place undue reliance on our forward-looking statements. Please see our periodic reports filed with the Securities and Exchange Commission (the “SEC”) for more information on these factors. Our forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as required by law, we are under no obligation to update any forward-looking statement, regardless of the reason the statement is no longer accurate.

## Market risk

As filed, 559 characters.

We do not maintain any derivative instruments, interest rate swap arrangements, hedging contracts, futures contracts or the like. Our primary market risk exposure is the changes in interest rates obtainable on our Credit Agreement. The interest on our Credit Agreement is based on a variable rate. At September 30, 2015, $46.0 million was outstanding under our Credit Agreement. Based on the balance of the Credit Agreement at September 30, 2015, any change in the interest rate of 1% would yield a decrease or increase in annual interest expense of $460,000.

## Controls and procedures

As filed, 1,386 characters.

(a) Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, the Company’s management completed an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures. Based on this evaluation, our principal executive officer and principal financial officer concluded (i) that our disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure and (ii) that our disclosure controls and procedures are effective.

(b) Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Filed Nov 5, 2015.
Source: SEC EDGAR, the filing index for accession 0001140361-15-039748. Last ingested by Listed: Nov 14, 2026, 13:45 ET. No prices; not investment advice.
